assessment of the quality of anti-vitamin K anticoagulation in a consecutive cohort of patients with non-valvular atrial fibrillation initiating such treatment (Q3138672)
Jump to navigation
Jump to search
Project Q3138672 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | assessment of the quality of anti-vitamin K anticoagulation in a consecutive cohort of patients with non-valvular atrial fibrillation initiating such treatment |
Project Q3138672 in Spain |
Statements
24,000.0 Euro
0 references
30,000.0 Euro
0 references
80.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
UNIVERSIDAD DE MURCIA
0 references
37°59'32.57"N, 1°7'49.94"W
0 references
30030
0 references
La fibrilación auricular se asocia con una disminución de la calidad de vida, y un aumento en la mortalidad y la morbilidad, fundamentalmente por su riesgo embólico. La anticoagulación oral, es esencial para la prevención eficaz del ictus en estos pacientes. Una baja calidad de la anticoagulación con antagonistas de la vitamina K (es decir, un INR lábil o un tiempo en rango terapéutico inferior al 65%) en pacientes con fibrilación auricular se traducirá en un mayor número de eventos adversos. Identificar los factores de conducen a una mala calidad de tratamiento anticoagulante nos permitirá identificar aquellos pacientes con mayor riesgo y establecer los cambios oportunos para que su manejo terapéutico sea más óptimo. Por otra parte, las complicaciones propias de la anticoagulación oral con antagonistas de la vitamina K (en especial las hemorrágicas) conducen con frecuencia al cese de este tratamiento (hecho que se ha asociado a un mayor número de eventos cardiovasculares entre ellos el ictus isquémico), siendo necesario evaluar a cada paciente para averiguar qué factores influyen en las decisiones sobre el tratamiento anticoagulante y en la aparición de eventos adversos, identificando los factores de riesgo que llevan a una baja adherencia terapéutica/abandono del tratamiento. (Spanish)
0 references
Atrial fibrillation is associated with a decrease in quality of life, and an increase in mortality and morbidity, mainly due to its embolic risk. Oral anticoagulation is essential for the effective prevention of stroke in these patients. A low quality of vitamin K antagonist anticoagulation (i.e. a labile INR or less than 65 %) in patients with atrial fibrillation will result in a greater number of adverse events. Identifying the factors leading to a poor quality of anticoagulant treatment will allow us to identify those patients at higher risk and to establish appropriate changes to make their therapeutic management more optimal. On the other hand, complications associated with oral anticoagulation with vitamin K antagonists (especially haemorrhagic) often lead to cessation of this treatment (a fact that has been associated with a greater number of cardiovascular events including ischemic stroke), and it is necessary to evaluate each patient to determine which factors influence decisions on anticoagulant treatment and on the occurrence of adverse events, identifying the risk factors that lead to a low therapeutic adherence/treatment abandonment. (English)
12 October 2021
0 references
Murcia
0 references
Identifiers
PI17_01375
0 references